{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:45Z","timestamp":1740107445270,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00280-023-04613-9","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T18:01:44Z","timestamp":1701367304000},"page":"329-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study"],"prefix":"10.1007","volume":"93","clinical-trial-number":[{"clinical-trial-number":"nct03082209","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-6557","authenticated-orcid":false,"given":"Carla","family":"Biesdorf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2286-0920","authenticated-orcid":false,"given":"Xiaowen","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satya R.","family":"Siddani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno C.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew","family":"Rasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-0449","authenticated-orcid":false,"given":"Rajeev M.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-6062","authenticated-orcid":false,"given":"Akshanth R.","family":"Polepally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"4613_CR1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nrc2465","volume":"8","author":"RW Johnstone","year":"2008","unstructured":"Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782\u2013798. https:\/\/doi.org\/10.1038\/nrc2465","journal-title":"Nat Rev Cancer"},{"key":"4613_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nrc821","volume":"2","author":"A Ashkenazi","year":"2002","unstructured":"Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420\u2013430. https:\/\/doi.org\/10.1038\/nrc821","journal-title":"Nat Rev Cancer"},{"key":"4613_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/cdd.2014.81","volume":"21","author":"J Lemke","year":"2014","unstructured":"Lemke J, von Karstedt S, Zinngrebe J, Walczak H (2014) Getting TRAIL back on track for cancer therapy. Cell Death Differ 21:1350\u20131364. https:\/\/doi.org\/10.1038\/cdd.2014.81","journal-title":"Cell Death Differ"},{"key":"4613_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cytogfr.2013.12.009","volume":"25","author":"PM Holland","year":"2014","unstructured":"Holland PM (2014) Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev 25:185\u2013193. https:\/\/doi.org\/10.1016\/j.cytogfr.2013.12.009","journal-title":"Cytokine Growth Factor Rev"},{"key":"4613_CR5","first-page":"31","volume":"299","author":"SK Kelley","year":"2001","unstructured":"Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA (2001) Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31\u201338","journal-title":"J Pharmacol Exp Ther"},{"key":"4613_CR6","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1124\/dmd.104.000323","volume":"32","author":"H Xiang","year":"2004","unstructured":"Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escand\u00f3n E (2004) Tissue distribution, stability, and pharmacokinetics of Apo2 ligand\/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 32:1230\u20131238. https:\/\/doi.org\/10.1124\/dmd.104.000323","journal-title":"Drug Metab Dispos"},{"key":"4613_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccr.2014.04.028","volume":"26","author":"JD Graves","year":"2014","unstructured":"Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T, Foltz IN, Chang W, Douangpanya H, Dang T, O\u2019Neill JW, Mallari R, Zhao X, Branstetter DG, Rossi JM, Long AM, Huang X, Holland PM (2014) Apo2L\/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 26:177\u2013189. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.028","journal-title":"Cancer Cell"},{"key":"4613_CR8","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/onc.2014.156","volume":"34","author":"MH Tuthill","year":"2015","unstructured":"Tuthill MH, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S, Newsom-Davis T, von Karstedt S, Graves J, Walczak H (2015) TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene 34:2138\u20132144. https:\/\/doi.org\/10.1038\/onc.2014.156","journal-title":"Oncogene"},{"key":"4613_CR9","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1158\/0008-5472.can-20-2178","volume":"81","author":"DC Phillips","year":"2021","unstructured":"Phillips DC, Buchanan FG, Cheng D, Solomon LR, Xiao Y, Xue J, Tahir SK, Smith ML, Zhang H, Widomski D, Abraham VC, Xu N, Liu Z, Zhou L, DiGiammarino E, Lu X, Rudra-Ganguly N, Trela B, Morgan-Lappe SE (2021) Hexavalent TRAIL fusion protein eftozanermin alfa optimally clusters apoptosis-Inducing TRAIL receptors to induce on-target antitumor activity in solid tumors. Cancer Res 81:3402\u20133414. https:\/\/doi.org\/10.1158\/0008-5472.can-20-2178","journal-title":"Cancer Res"},{"key":"4613_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS (2020) Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 17:395\u2013417. https:\/\/doi.org\/10.1038\/s41571-020-0341-y","journal-title":"Nat Rev Clin Oncol"},{"key":"4613_CR11","doi-asserted-by":"publisher","first-page":"e0198203","DOI":"10.1371\/journal.pone.0198203","volume":"13","author":"L Danish","year":"2018","unstructured":"Danish L, Imig D, Allg\u00f6wer F, Scheurich P, Pollak N (2018) Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. PLoS ONE 13:e0198203. https:\/\/doi.org\/10.1371\/journal.pone.0198203","journal-title":"PLoS ONE"},{"key":"4613_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/sj.cgt.7700792","volume":"12","author":"L Zhang","year":"2005","unstructured":"Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228\u2013237. https:\/\/doi.org\/10.1038\/sj.cgt.7700792","journal-title":"Cancer Gene Ther"},{"key":"4613_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202\u2013208. https:\/\/doi.org\/10.1038\/nm.3048","journal-title":"Nat Med"},{"key":"4613_CR14","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood.V130.Suppl_1.2812.2812","volume":"130","author":"SK Tahir","year":"2017","unstructured":"Tahir SK, Smith ML, Solomon LR, Zhang H, Xue JC, Xiao Y, Cheng D, Buchanan G, Morgan-Lappe S, Phillips DC (2017) ABBV-621 is a novel and potent TRAIL receptor agonist fusion protein that induces apoptosis alone and in combination with navitoclax and venetoclax in hematological tumors. Blood 130:2812\u20132812. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.2812.2812","journal-title":"Blood"},{"key":"4613_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s10637-022-01247-1","volume":"40","author":"P LoRusso","year":"2022","unstructured":"LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJA, Moreno V, Carneiro BA, Devriese LA, Petrich A, Modi D, Morgan-Lappe S, Nuthalapati S, Motwani M, Dunbar M, Glasgow J, Medeiros BC, Calvo E (2022) Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs 40:762\u2013772. https:\/\/doi.org\/10.1007\/s10637-022-01247-1","journal-title":"Invest New Drugs"},{"key":"4613_CR16","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood.2022017333","volume":"141","author":"SK Tahir","year":"2023","unstructured":"Tahir SK, Calvo E, Carnero BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, Gort E, Ishizawa K, Morillo D, Biesdorf C, Smith M, Cheng D, Motwani M, Sharon D, Uziel T, Modi DA, Buchanan FG, Morgan-Lappe S, Medeiros BC, Phillips DC (2023) Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood 141:2114\u20132126. https:\/\/doi.org\/10.1182\/blood.2022017333","journal-title":"Blood"},{"key":"4613_CR17","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/s0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041\u20131047. https:\/\/doi.org\/10.1016\/s0140-6736(00)02034-1","journal-title":"Lancet"},{"key":"4613_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/dmd.116.071613","volume":"45","author":"H Liu","year":"2017","unstructured":"Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, Serby M, Vaidyanathan S, Wong SL, Agarwal S, Dunbar M, Sydor J, de Morais SM, Lee AJ (2017) Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of Its unusual metabolites. Drug Metab Dispos 45:294\u2013305. https:\/\/doi.org\/10.1124\/dmd.116.071613","journal-title":"Drug Metab Dispos"},{"key":"4613_CR19","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1002\/jps.24444","volume":"104","author":"L Liu","year":"2015","unstructured":"Liu L (2015) Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci 104:1866\u20131884. https:\/\/doi.org\/10.1002\/jps.24444","journal-title":"J Pharm Sci"},{"key":"4613_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1517\/17425255.2012.673585","volume":"8","author":"X Chen","year":"2012","unstructured":"Chen X, Zaro JL, Shen WC (2012) Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opin Drug Metab Toxicol 8:581\u2013595. https:\/\/doi.org\/10.1517\/17425255.2012.673585","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4613_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4331\/wjbc.v3.i4.73","volume":"3","author":"Y Vugmeyster","year":"2012","unstructured":"Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW (2012) Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem 3:73\u201392. https:\/\/doi.org\/10.4331\/wjbc.v3.i4.73","journal-title":"World J Biol Chem"},{"key":"4613_CR22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/aps.2012.51","volume":"33","author":"L Zhao","year":"2012","unstructured":"Zhao L, Ren TH, Wang DD (2012) Clinical pharmacology considerations in biologics development. Acta Pharmacol Sin 33:1339\u20131347. https:\/\/doi.org\/10.1038\/aps.2012.51","journal-title":"Acta Pharmacol Sin"},{"key":"4613_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493\u2013507. https:\/\/doi.org\/10.2165\/11531280-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"4613_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","volume":"9","author":"L Liu","year":"2018","unstructured":"Liu L (2018) Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 9:15\u201332. https:\/\/doi.org\/10.1007\/s13238-017-0408-4","journal-title":"Protein Cell"},{"key":"4613_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A (2016) Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 6:1106\u20131117. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0313","journal-title":"Cancer Discov"},{"key":"4613_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/jcph.821","volume":"57","author":"AH Salem","year":"2017","unstructured":"Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL (2017) Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-hodgkin lymphoma. J Clin Pharmacol 57:484\u2013492. https:\/\/doi.org\/10.1002\/jcph.821","journal-title":"J Clin Pharmacol"},{"key":"4613_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374:311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1513257","journal-title":"N Engl J Med"},{"key":"4613_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B (2012) Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J 14:296\u2013302. https:\/\/doi.org\/10.1208\/s12248-012-9340-y","journal-title":"AAPS J"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04613-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04613-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04613-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T15:04:49Z","timestamp":1710860689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04613-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["4613"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04613-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carla Biesdorf, Satya R. Siddani, David Hoffman, Nils Boehm, Bruno C. Medeiros, Rajeev M. Menon, and Akshanth R. Polepally are current employees of AbbVie Inc. and may own stock. Xiaowen Guan was an employee of AbbVie Inc. at the time of study conduct and may own stock. Toshihiko Doi is an employee of National Cancer Center Hospital East and has received research funding from Abbvie, Inc., Maja de Jonge is an employee of Erasmus Medisch Centrum and has received research funding from Abbvie, Inc., Drew Rasco is an employee of South Texas Accelerated Research Therapeutics (START) and has received research funding from Abbvie, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol and all other study-related documents were reviewed and approved by an ethics committee\/independent institutional review board (IRB) at each participating site. All subjects provided written, informed consent prior to the start of any screening or study-specific procedures. The study was conducted in accordance with the protocol, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, applicable regulations, and guidelines governing clinical study conduct and ethical principles that have their origin in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}